BMJ Open Systematic review and meta-analysis of the association between peripheral inflammatory cytokines and generalised anxiety disorder

Harry Costello, Rebecca L Gould, Esha Abrol, Robert Howard

To cite: Costello H, Gould RL, Abrol E, *et al*. Systematic review and meta-analysis of the association between peripheral inflammatory cytokines and generalised anxiety disorder. *BMJ Open* 2019;9:e027925. doi:10.1136/bmjopen-2018-027925

► Prepublication history and additional material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2018-027925>).

Received 14 November 2018

Revised 3 April 2019

Accepted 30 May 2019

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ.

Division of Psychiatry, University College London, London, UK

Correspondence to

Dr Harry Costello;
harry.costello@ucl.ac.uk

ABSTRACT

Objective Inflammation has been implicated in the aetiology of mental illness. We conducted the first systematic review and meta-analysis of the association between peripheral markers of inflammation and generalised anxiety disorder (GAD).

Design Systematic review and meta-analysis of studies measuring peripheral cytokine levels in people with GAD compared with controls.

Data sources MEDLINE (1950–), EMBASE (1947–), PsycINFO (1872–) and Web of Science (1945–) databases up until January 2018.

Eligibility criteria Primary, quantitative research studies of people with a diagnosis of GAD assessed using a standardised clinical interview that measured peripheral inflammatory markers.

Data extraction and synthesis Two independent reviewers extracted data and assessed study quality. Meta-analysis using a random-effects model was conducted for individual cytokines where data from three or more studies were available.

Results 14 of 1718 identified studies met the inclusion criteria, comprising 1188 patients with GAD and 10 623 controls. In total 16 cytokines were evaluated. Significantly raised levels of C reactive protein (CRP), interferon- γ and tumour necrosis factor- α were reported in patients with GAD compared with controls in two or more studies. Ten further proinflammatory cytokines were reported to be significantly raised in GAD in at least one study. However, 5 of 14 studies found no difference in the levels of at least one cytokine. Only CRP studies reported sufficient data for meta-analysis. CRP was significantly higher in people with GAD compared with controls, with a small effect size (Cohen's $d=0.38$, $0.06-0.69$), comparable with that reported in schizophrenia. However, heterogeneity was high ($I^2=75\%$), in keeping with meta-analyses of inflammation in other psychiatric conditions and reflecting differences in participant medication use, comorbid depression and cytokine sampling methodology.

Conclusion There is preliminary evidence to suggest an inflammatory response in GAD, but it remains unclear whether inflammatory cytokines play a role in the aetiology. GAD remains a poorly studied area of neuroinflammation compared with other mental disorders, and further longitudinal studies are required.

Strengths and limitations of this study

- This is the first study to conduct a comprehensive systematic review and meta-analysis of peripheral inflammatory markers in generalised anxiety disorder.
- A wide range of databases were searched and a large number of papers screened for inclusion in the study, 14 of which were subjected to quality assessment and detailed critical appraisal.
- It was only possible to conduct a meta-analysis of C reactive protein, and it was not possible to examine publication bias due to the limited number of studies identified for inclusion in the meta-analysis.
- The high levels of heterogeneity across studies mean that findings should be interpreted with caution.

INTRODUCTION

There is growing evidence for immune-mediated pathogenic mechanisms in several psychiatric disorders with discrete profiles of inflammatory mechanisms.¹ Epidemiological evidence has shown an increased risk of mood disorders and psychosis in people with a history of severe infection or autoimmune conditions.^{2 3} This has been supported by genome-wide association studies implicating multiple immune signalling pathways,⁴ and altered profiles of proinflammatory cytokines and acute phase reactants in schizophrenia,⁵ depression,⁶ obsessive compulsive disorder (OCD)⁷ and bipolar disorder.⁸ However, the relationship between inflammation and mental illness remains poorly understood and controversial, with a number of proposed potential neuropathological mechanisms,^{9 10} including changes in microglial function,¹ glutamatergic excitotoxicity,¹¹ synaptic plasticity¹² and reduced hippocampal neurogenesis.¹³

Despite increasing interest in the role of inflammation in mental illness, relatively little research has focused on potential associations

with anxiety disorders.¹⁴ These are common, with an estimated lifetime prevalence of 7.3%–28.8%, are associated with substantial functional impairment and are estimated to cost between \$42 and \$47 billion to the US economy each year.^{15 16} However, only 60% of patients are thought to respond to pharmacological and psychological treatments, and understanding of the underlying pathophysiological mechanisms of anxiety disorders remains poor.¹⁷

Generalised anxiety disorder (GAD) is the most common anxiety disorder, with a degree of associated disability equivalent to that of major depressive disorder (MDD).¹⁸ Despite psychopharmacological¹⁹ and psychological²⁰ treatments showing effectiveness in GAD, 42% of people living with GAD experience ongoing symptoms after 12 years, and half of remitted patients experience recurrence.¹⁸ GAD is more prevalent in those with inflammatory conditions such as rheumatoid arthritis (RA),^{21 22} with case series studies suggesting symptoms are less common with immune-modulating treatment targeting specific inflammatory cytokines.²³ The chronic clinical course and relatively high probability of recurrence in GAD, in addition to preliminary evidence of an inflammatory component in other anxiety disorders,^{7 24} suggest that inflammation could be an important neurobiological mechanism in the aetiology of this disorder.

To date, two previous reviews of inflammatory biomarkers in GAD have been conducted. Of these, however, one was a narrative review²⁵ and the other was restricted to literature published within the last decade,¹⁴ and with a focus on all anxiety disorders. Both reviews reported that there was preliminary evidence for inflammatory changes in GAD. However, only three studies were identified by the systematic review reporting cytokine changes in GAD and no meta-analysis was performed. No study to date has conducted a comprehensive systematic review and meta-analysis of all current literature focusing on GAD or commented on the longitudinal association between inflammation and GAD.

We aimed to systematically review the cross-sectional and longitudinal associations between inflammatory biomarkers and GAD, and perform the first meta-analysis of inflammatory biomarkers in GAD.

METHODS

We conducted a systematic review of studies that had included people with GAD who had undergone peripheral cytokines measurement and a between-group meta-analysis of cytokine levels in people with GAD compared with controls. We conducted the study according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.²⁶

We searched MEDLINE (1950–), EMBASE (1947–), PsycINFO (1872–) and Web of Science (1945–) databases up until January 2018. Reference lists of eligible studies were then searched for further ones that met the eligibility criteria.

Our search terms (see online supplementary appendix 1 for further details) were the following: (inflammat* or cytokine or interferon or IFN or interleukin or 'translocator protein' or TSPO or 'tumour necrosis factor' or 'tumor necrosis factor' or TNF or IL-1 or IL-2 or IL-4 or IL-7 or IL-6 or IL-8 or IL-10 or microglia or t-cell or lymphocyte or 'C-reactive protein' or 'C reactive protein' or CRP or 'acute phase protein' or 'fibrinogen') and ('generalised anxiety disorder' or 'generalized anxiety disorder' or GAD or worry).

We included primary, quantitative research studies (including unpublished theses and dissertations), written in any language, that included people with a diagnosis of GAD assessed using standardised clinical interview (eg, Structured Clinical Interview for DSM²⁷) or standardised psychometric instruments. Studies reported cross-sectional or longitudinal data in clinical or community populations. Cross-sectional studies measured inflammatory biomarker concentrations in anxious people versus non-anxious healthy controls, while longitudinal studies measured inflammatory biomarker concentrations at baseline and anxiety scores at follow-up. Inflammatory markers were measured in the unstimulated state (no antigen-induced stimulation of cytokine production) and sampled from peripheral blood, cerebrospinal fluid (CSF) or saliva at any time of day. Exclusion criteria included studies with less than five participants, studies on animals and studies where subjects were participants in the treatment arms of clinical trials.

Patient and public involvement

There was no patient or public involvement in the study.

Data extraction and quality assessment

Data were extracted and quality assessed for all studies that met the eligibility criteria by two independent raters (HC, EA), with disagreements settled by consensus and discussion. For each cytokine, we extracted the means, variance estimates or 95% CIs and sample size for GAD and control groups. We also extracted demographic data (eg, age, sex) and clinical data (eg, medication use, comorbid depression, severity) where available. Authors were contacted for further information, where necessary.

Risk of bias and study quality were evaluated using the Newcastle-Ottawa Quality Assessment Scale.²⁸ Other potential confounding factors (including assay type and sensitivity, inflammatory marker analysis and recruitment methods) were also examined to allow more detailed bias and quality analysis of studies.

Strategy for data synthesis

Separate meta-analyses were performed for individual biomarkers in GAD versus controls if sufficient data were available from a minimum of three studies. Due to different measurement methods and anticipated high heterogeneity, we estimated a standardised mean difference (SMD) for each inflammatory marker and used a random-effects model for meta-analysis, conducted using

Figure 1 Flow of studies in the systematic review and meta-analysis. GAD, generalised anxiety disorder.

RevMan V.5. Heterogeneity across studies was quantified with the I^2 statistic, with a value of 25% typically regarded as low, 50% as medium and 75% as high.²⁹ If studies were longitudinal or trials of interventions with multiple data collection points, we examined baseline data only to avoid skewed meta-analysis from inclusion of more than one effect size from the same study.

RESULTS

Systematic review

We identified 1718 papers, excluded 1598 of these by titles and abstracts, and retrieved the remaining 120 papers, of which 14 met the eligibility criteria and were included in the final systematic review (see figure 1).

The primary reasons for rejection were that no diagnosis of GAD was recorded or no inflammatory marker was measured.

The characteristics of the 14 included studies are shown in tables 1 and 2. Studies comprised a total of 1188 people with a diagnosis of GAD and 10623 controls, with a further 116 participants from a study that did not report GAD and control group sizes.

In total, 16 different cytokines were evaluated (see table 2). C reactive protein (CRP) (9/14 studies, 64.2%), tumour necrosis factor- α (TNF- α) (6/14 studies, 42.9%), interleukin-6 (IL-6) (5/14 studies, 35.7%) and interferon- γ (IFN- γ) (3/14 studies, 21.4%) were the most commonly studied. All other cytokines were only analysed in two or less studies.

Table 1 Study and clinical characteristics

Study	Country	Study type	Inflammatory markers	N		Standardised diagnostic assessment/ crit era	Anxiety measure	Age (years, SD)		% Female		BMI		Current smoking	Medicated	Physical health comorbidities	Mental health comorbidities
				GAD	Control			GAD	Control	GAD	Control	GAD	Control				
Bankier <i>et al</i> ²⁸	USA	Case-control	CRP	15	30	SCID, DSM-IV	NR	NR	67.6 (12.7)	NR	33%	NR	NR	GAD: NR Controls: 10%	NR	All participants had CVD. Excluded other conditions.	Excluded.
Copeland <i>et al</i> ²⁹	USA	Cohort, prospective	CRP	146	5664	Child and Adolescent Psychiatric Assessment <16, Young Adult Psychiatric Assessment >16, DSM-IV criteria	Total number of anxiety symptoms (range: 0-6)	14.21, all subjects (odds or means ratio 1.03-1.22) with GAD dx	48.7% (odds or means ratio 2.02 (1.04-3.92) with GAD dx)	NR	51.40%	22.37 (5.62) (odds or means ratio 1.08 (1.05-1.11) with GAD dx)	22.45 (3.27)	Total sample: 13.5% (odds/means ratio with GAD: 2.86)	30.2% 'use medication' (odds/means ratio with GAD: 2.00)	34.7% had 'recent health ailments'.	Total sample: 39.9% comorbid MDD.
De Berardis <i>et al</i> ⁴²	Canada	Cross-sectional	CRP	70	No control	SCID, DSM-IV	HAM-A (score >20 for inclusion)	28.2 (5.3)	-	51.40%	-	22.1 (1.67)	-	NR	Excluded.	Excluded.	Total sample: 44.3% of participants had alexithymia. Excluded other comorbid mental illness.
Hoge <i>et al</i> ⁴⁴	USA	RCT	TNF- α , IL-6	70	No control	SCID, DSM-IV	NR	39.12	-	45.70%	-	NR	-	NR	Excluded.	Excluded.	GAD: 14.3% comorbid MDD. Excluded other comorbid mental illness.
Hou <i>et al</i> ⁴⁷	UK	Case-control	IL-4, IL-10, TNF- α , IFN- γ	54	64	MINI, DSM-IV, ICD-10 criteria	HADS, GAD-7 (score >10 for inclusion)	35.06 (14.45)	25.75 (8.87)	34%	50%	24.84 (5.70)	22.45 (3.27)	GAD: 22% Controls: 34%	GAD: 67% use 'anxiolytic' medication. Excluded other medication use.	Excluded.	Excluded.
Khandaker <i>et al</i> ⁴³	UK	Cohort, prospective	CRP	26	3392	DAWBA, DSM-IV criteria	DAWBA	15.56 (0.24)	15.53 (0.31)	90%	52.30%	22.55 (3.52)	21.40 (3.63)	NR	NR	NR	GAD: 30.77% comorbid MDD. Excluded other comorbid mental illness.
Korkkela <i>et al</i> ⁴⁰	Finland	Cross-sectional	CRP, TNF- α , IFN- γ	116		MINI	NR	NR	NR	100%	100%	All 25.3 (5.0)	NR	Excluded.	NR	NR	NR
Nayek and Ghosh ³⁴	India	Case-control	CRP	50	50	ICD-10	NR	37.96 (10.7)	37.00 (12.08)	54%	23%	NR	NR	Excluded.	Excluded if using HRT or OCP. Other medications not reported.	Excluded.	NR
Ogodek <i>et al</i> ⁴⁶	Poland	Case-control	SDF-1, CCL-5, MCP-1	120	40	DSM-V	NR	41.4 (3.5)	40.8 (3.1)	50%	NR	NR	NR	NR	Excluded.	Excluded.	All participants had comorbid personality disorder. Excluded other comorbid mental illness.

Continued

Table 1 Continued

Study	Country	Study type	Inflammatory markers	N		Standardised diagnostic assessment/crit era	Anxiety measure	Age (years, SD)		% Female		BMI		Current smoking	Medicated	Physical health comorbidities	Mental health comorbidities
				GAD	Control			GAD	Control	GAD	Control	GAD	Control				
Tang <i>et al</i> ⁴⁵	China	Case-control	CRP, IL-1 α , IL-2, IL-5, IL-6, IL-8, IL-12p70, IFN- γ , GM-CSF	48	48	MINI, DSM-IV	GAD-7, SAI, TAI	40.75 (12.21)	39.56 (10.06)	58.33%	64.17%	22.56 (2.73)	22.69 (2.63)	GAD: 29% Controls: 23%	Excluded.	Excluded acute illness. Chronic comorbidities NR.	Excluded.
Tofani <i>et al</i> ⁴⁶	Italy	Case-control	IL-2, IL-10	14	10	MINI, DSM-IV	GAD-7	NR	NR	NR	NR	NR	NR	NR	Excluded.	NR	Excluded.
Vogelzangs <i>et al</i> ⁴⁶	Holland	Cohort	CRP, IL-6, TNF- α	454	556	CIDI, DSM criteria	BAI	Total sample: 41.8 (13.1)	NR	66.90%	NR	25.6 (5.1)	NR	Total sample: 38.2%	NR	Total sample: 6.2% CVD, 58.4% comorbid 4.9% diabetes, mean of 0.4 excluded other chronic comorbid mental illness.	Total sample: 58.4% comorbid MDD.
Yang <i>et al</i> ⁴⁵	China	Case-control	IL-1, IL-4, TNF- α	28	41	MINI, DSM-IV	HAM-A	55.1 (6.9)	55.9 (5.6)	53.60%	48.80%	22.0 (4.4)	22.5 (3.7)	GAD: 35.7% Control: 24.4%	Excluded.	Additional group with comorbid asthma. Excluded other comorbidities.	Excluded.
Zahn ⁴¹	USA	Cohort, prospective	CRP, IL-6, TNF- α	93	728	CDIS, DSM-IV	NR	68 (9.6)	NR	17%	NR	NR	NR	NR	NR	All patients had history of CVD.	GAD: 60.0% comorbid MDD, 86.2% had lifetime history MDD.

–, not applicable; BAI, Beck Anxiety Inventory; CCL-5, chemokine C-C motif ligand 5; CDIS, Computerized Diagnostic Interview Schedule; CIDI, Composite Interview Diagnostic Instrument; CRP, C reactive protein; CVD, cardiovascular disease; DAWBA, Development and Well-Being Assessment; DSM, Diagnostic and Statistical Manual of Mental Disorders; dx, diagnosis; GAD, generalised anxiety disorder; GAD-7, Generalised Anxiety Disorder Assessment; GM-CSF, granulocyte-macrophage colony-stimulating factor; HADS, Hospital Anxiety and Depression Scale; HAM-A, Hamilton Anxiety Rating Scale; HRT, hormone replacement therapy; ICD, International Classification of Diseases; IFN- γ , interferon- γ ; IL, interleukin; MCP-1, monocyte chemoattractant protein-1; MDD, major depressive disorder; MINI, Mini-International Neuropsychiatric Interview; NR, not reported; OCP, oral contraceptive pill; RCT, randomised controlled trial; SAI, State Anxiety Inventory, SCID, Structured Clinical Interview for DSM-IV; SDF-1, stromal derived factor-1; TAI, Test Anxiety Inventory; TNF- α , tumour necrosis factor- α .

Table 2 Inflammatory marker sampling and analysis

Study	GAD	Control	Inflammatory markers	Nature of sample	Cross-sectional or longitudinal	Time of day of sample	Fasted period before sample	Assay method	Assay sensitivity reported	Inflammatory marker cut-off used	Confounding factors controlled for
Bankier <i>et al</i> ³³	15	30	CRP	Blood	Cross-sectional	NR	NR	High sensitivity turbidimetric immunoassay	Yes	CRP >3 mg/L for significance	Age, sex, education, MDD, obesity, smoking history, type II diabetes mellitus, hypertension, hyperlipidaemia, other mental illness.
Copeland <i>et al</i> ³⁹	146	5664	CRP	Whole blood spots	Longitudinal: sampled aged 9–16, 19 and 21 years old	NR	NR	Biotin-streptavidin-based immunofluorometric system	Yes	Excluded if >10 mg/L	Age, sex, race, SES, BMI, medication use, substance use, recent physical illness, chronic illness.
De Berardis <i>et al</i> ⁴²	70	No control	CRP	Serum	Cross-sectional	07:00–08:30	10-hour fast	Highly sensitive nephelometric assay	Yes	No	Age, sex, BMI, MDD, physical illness, other mental illness, medication use
Hoge <i>et al</i> ⁴⁴	70	No control	TNF- α , IL-6	Plasma	Longitudinal: sampled prepsychological and postpsychological intervention	13:00–16:30	NR	NR	No	No	Age, sex, ethnicity, MDD, medication use, physical illness, other mental illness
Hou <i>et al</i> ⁴⁷	54	64	IL-4, IL-10, TNF- α , IFN- γ	Serum	Cross-sectional	09:00–10:00	NR	Multiplex ultrasensitive immunoassay	Yes	No	Age, sex, BMI, smoking, alcohol consumption, MDD, physical illness, other mental illness.
Khandaker <i>et al</i> ³³	26	3392	CRP	Serum	Cross-sectional	NR	'Overnight'	Automated particle-enhanced immunoturbidimetric assay	No	Excluded if >10 mg/L	Age, sex, parental SES, ethnicity, maternal age at delivery, concurrent infection, family history of inflammatory disease, MDD.
Korkeila <i>et al</i> ⁴⁰	116		CRP, TNF- α , IFN- γ	Blood	Cross-sectional	NR	NR	NR	No	No	BMI.
Nayek and Ghosh ³⁴	50	50	CRP	Serum	Cross-sectional	NR	NR	Particle-enhanced turbidimetric immunoassay technique	No	Excluded if 'raised ESR'	Age, sex, SES, religion, marital status, locality, BMI >30, physical illness.

Continued

Table 2 Continued

Study	GAD	Control	Inflammatory markers	Nature of sample	Cross-sectional or longitudinal	Time of day of sample	Fasted period before sample	Assay method	Assay sensitivity reported	Inflammatory marker cut-off used	Confounding factors controlled for
Oglodek <i>et al</i> ⁴⁸	120	40	SDF-1, CCL-5, MCP-1	Plasma	Cross-sectional	07:00–09:00	Fasted, duration NR	ELISA	Yes	No	Sex, other mental illness, physical illness, substance misuse, smoking status, medication use.
Tang <i>et al</i> ³⁵	48	48	CRP, IL-1 α , IL-2, IL-5, IL-6, IL-8, IL-12p70, IFN- γ , GM-CSF	Serum	Cross-sectional	09:00–10:00	NR	ELISA	No	No	Age, sex, education, BMI, smoking status, alcohol consumption, acute physical illness, other mental illness, medication use.
Tofani <i>et al</i> ⁴⁶	14	10	IL-2, IL-10	Plasma	Cross-sectional	NR	NR	Immunoenzymatic assay	No	No	Medication use.
Vogelzangs <i>et al</i> ³⁶	454	556	CRP, IL-6, TNF- α	Plasma	Cross-sectional	08:00–09:00	'Overnight'	ELISA	Yes	No	Age, sex, education, smoking status, alcohol intake, physical activity, BMI, physical illness, medication use, MDD, other mental illness.
Yang <i>et al</i> ⁴⁵	28	41	IL-1, IL-4, IL-6, TNF- α	Saliva	Cross-sectional	NR	'Overnight'	ELISA	Yes	No	Age, sex, smoking status, BMI, medication use, physical illness, other mental illness.
Zahm ⁴¹	93	728	CRP, IL-6, TNF- α	Serum	Cross-sectional	No (fasting, duration NR)	Fasted, duration NR	ELISA	Yes	No	Age, sex, SES, BMI, illicit substance use, alcohol use, smoking status, physical activity, physical illness.

BMI, body mass index; CCL-5, chemokine C-C motif ligand 5; CRP, C reactive protein; ESR, erythrocyte sedimentation rate; GAD, generalised anxiety disorder; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN- γ , interferon- γ ; IL, interleukin; MCP-1, monocyte chemoattractant protein-1; MDD, major depressive disorder; NR, not reported; SDF-1, stromal derived factor-1; SES, socioeconomic status; TNF- α , tumour necrosis factor- α .

Twelve studies (85.7%) reported the assay method used, all of which were versions of an ELISA or enzyme immunoassay. However, only seven studies (50%) reported assay sensitivity. All but one study used blood component samples to assess inflammatory marker levels, with the most common sample type being serum ($n=6$, 42.9%) and plasma ($n=4$, 28.6%).

Risk of bias and quality in individual studies

All included studies had adequate case definition, with participants meeting the diagnostic criteria for GAD according to the Diagnostic and Statistical Manual of Mental Disorders (DSM) or the International Classification of Diseases, with 12 studies (85.7%) using a structured clinical interview for assessment (see [table 1](#)).

Most (71.4%) studies included people aged 18–65, but two studies (14.3%) only included participants over the age of 50 and a further two studies (14.3%) used adolescent participant cohorts. The majority (78.6%) of studies accounted for age and sex differences in their analyses. Only 8 of 14 (57.1%) studies recorded participants' body mass index (BMI), which is known to correlate with inflammation, and only half of these accounted for BMI differences in analysis of group differences³⁰ (see [table 2](#)).

Use of psychotropic medication and the presence of comorbid MDD are important moderators of inflammation in other psychiatric disorders.²⁴ Six studies (42.8%) excluded patients who used psychiatric or other immune-modulating medication, although only two studies (4.3%) reported medication use. The majority of studies (64.2%) either excluded patients with comorbid MDD or adjusted for this in the analyses.

Concurrent physical illness is clearly an important determinant of inflammatory cytokine levels, and this was accounted for by the majority of included studies by either excluding participants with comorbidities (5 studies, 35.7%) or adjusting for chronic physical illness in group comparisons (6 studies, 42.8%), although two studies specifically only included participants with comorbid cardiovascular disease (CVD). Use of a predetermined cut-off value for cytokine levels was employed by three studies (21.4%) to ensure that cases with acute infection were excluded from the sample.

Many inflammatory markers exhibit a diurnal pattern of expression and are affected by consumption of food; thus, time of day of sampling and whether the sample was taken in a fasted state are important factors to consider in analysing relative levels of cytokines.³¹ However, time of day of sampling was only recorded in a minority of studies (6 studies, 42.8%), and the same number of studies recorded whether fasted samples were taken.

The overall quality of studies included in the review varied significantly, with Newcastle-Ottawa Scale scores ranging from 2 to 9 (see [table 3](#)). The area in which most studies were inadequate was in reporting non-response rate and detailing recruitment methods (see [table 3](#)). Lowest quality studies were abstracts or dissertations, and

two studies lacked control groups as only patients with GAD were sampled (see [table 4](#)).

C reactive protein

CRP is a critical early proinflammatory surveillance molecule involved in the activation of the complement system and both innate and adaptive immune systems.³² We identified nine studies that investigated the association between GAD and CRP, comprising a total of 11 486 participants (see [table 5](#)).

Four studies, involving 578 patients with GAD and 4046 controls, provided sufficient information to conduct a meta-analysis of CRP levels in GAD^{33–36} (see [figure 2](#)). This was the only inflammatory marker for which meta-analysis was possible. Meta-analysis showed significantly raised CRP in GAD compared with controls (SMD 0.38, 95% CI 0.06 to 0.69; $Z=2.36$, $p=0.02$). However, there was a large and statistically significant degree of heterogeneity between studies ($X^2=12.0$; $df=3$; $p=0.007$; $I^2=75\%$). Given the high heterogeneity and inclusion of less than 10 studies in the meta-analysis, we did not have sufficient power to examine publication bias.³⁷ Two out of four studies were of high quality, scoring 9 on the Newcastle-Ottawa Scale, and examined large sample sizes^{33 36} (see [table 4](#)). However, in each of the four meta-analysed studies, different assay methods were used and sampling methods varied significantly (see [table 2](#)). The lowest quality study to be included in the meta-analysis did not report mental health comorbidities and recruited participants from an inpatient setting.³⁴ There was also a wide range in the age of participants included in the four studies, with the largest study examining CRP levels in adolescents, which would likely contribute to high heterogeneity.

Five studies^{33–36 38} ($n=4669$), one of which was conducted in children aged 16 years old³³ and two in participants with comorbid heart disease,³⁸ reported significantly higher CRP levels in participants with a diagnosis of GAD. The largest study³⁹ ($n=5810$) examining CRP in GAD examined CRP levels in children from baseline measurement aged 9–16 years to follow-up at age 19–21. This was the only study to examine the longitudinal association between GAD and CRP, and found a bivariate association both cross-sectionally and over time between GAD and elevated CRP; however, this was accounted for by potential covariates, including BMI and medication use. The only study⁴⁰ to find an inverse correlation between CRP and GAD was conducted in non-smoking women from a study in Finland and did not specify the numbers of participants with a diagnosis of GAD or group differences.

No difference was found in a cohort study ($n=821$) that used a combined inflammatory index consisting of CRP, IL-6 and TNF- α in 93 patients with a diagnosis of GAD and controls with a history of CVD.⁴¹ Subgroup analysis examining differences in individual inflammatory markers was not reported.⁴¹

We found two studies^{35 42} ($n=196$) that examined the association of severity of GAD symptoms with CRP level.

Table 3 Summary inflammatory marker findings in GAD

Study	N		Findings
	Controls	With GAD (n)	
CRP			
Bankier <i>et al</i> ³⁸	30	15	↑ in GAD with comorbid CVD compared with controls using a dichotomous outcome of CRP cut-off score (CRP >3 mg/L).
Copeland <i>et al</i> ³⁹	5664	146	Longitudinal study in adolescents: ↑ bivariate association both cross-sectionally and over time between GAD and elevated CRP, but accounted for by medication use and BMI.
De Berardis <i>et al</i> ⁴²	No control	70	↑ in patients with GAD with comorbid alexithymia and with increased suicidal ideation, no control group.
Khandaker <i>et al</i> ³³	3392	26	↑ in children aged 16 years old with GAD compared with controls, remained ↑ after adjusting for covariates.
Korkeila <i>et al</i> ⁴⁰	116		↓ in non-smoking women with a diagnosis of GAD compared with controls; however, control group was not described.
Nayek and Ghosh ³⁴	50	50	↑ in patients with GAD compared with controls.
Tang <i>et al</i> ³⁵	48	48	↑ in patients with GAD compared with controls and ↑ with increased severity of GAD.
Vogelzangs <i>et al</i> ³⁶	556	454	↑ in patients with GAD compared with controls in unadjusted data obtained from the authors.
Zahm ⁴¹	728	93	↔ between those with and without a current GAD diagnosis (p=0.28) or with and without a lifetime GAD diagnosis, using a combined inflammatory index of CRP, IL-6 and TNF-α measurements.
IL-1			
Yang <i>et al</i> ⁴⁵	41	28	↑ sputum IL-1 in patients aged 50–60 years old with GAD compared with controls.
IL-1α			
Tang <i>et al</i> ³⁵	48	48	↑ IL-1α in patients with GAD compared with controls and ↑ with increased severity of GAD.
IL-2			
Tang <i>et al</i> ³⁵	48	48	↑ in patients with GAD compared with controls (p<0.001) but ↔ with severity of GAD.
Tofani <i>et al</i> ⁴⁶	10	14	↔ in patients with GAD compared with controls.
IL-4			
Hou <i>et al</i> ⁴⁷	64	54	↔ in patients with GAD compared with controls.
IL-5			
Tang <i>et al</i> ³⁵	48	48	↔ in patients with GAD compared with controls, or association with severity of GAD.
IL-6			
Hoge <i>et al</i> ⁴⁴	–	70	No control group: RCT of psychological intervention in GAD.
Tang <i>et al</i> ³⁵	48	48	↑ in patients with GAD compared with controls and ↑ with increased severity of GAD.
Vogelzangs <i>et al</i> ³⁶	556	454	↑ in patients with GAD compared with controls in unadjusted data obtained from author, but ↔ between IL-6 and GAD compared with other anxiety disorders.
Yang <i>et al</i> ⁴⁵	41	28	↑ sputum in patients with GAD aged 50–60 years old compared with controls.
Zahm ⁴¹	728	93	↔ between those with and without a current GAD diagnosis or with and without a lifetime GAD diagnosis, using a combined inflammatory index of CRP, IL-6 and TNF-α measurements.
IL-8			
Tang <i>et al</i> ³⁵	48	48	↑ in patients with GAD compared with controls and ↑ with increased severity of GAD.
IL-10			
Hou <i>et al</i> ⁴⁷	64	54	↓ in patients with GAD compared with controls, which remained ↓ after adjustment for covariates.

Continued

Table 3 Continued

Study	N		Findings
	Controls	With GAD (n)	
Tofani <i>et al</i> ⁴⁶	10	14	↑ in GAD compared with controls. <i>IL-12p70</i>
Tang <i>et al</i> ³⁵	48	48	↑ in patients with GAD compared with controls but ↔ with severity of GAD. <i>IFN-γ</i>
Hou <i>et al</i> ⁴⁷	64	54	↑ in patients with GAD compared with controls which remained ↑ after adjustment for covariates.
Korkeila <i>et al</i> ⁴⁰	116		↓ in non-smoking women with a diagnosis of GAD compared with controls; however, control group was not described.
Tang <i>et al</i> 2017 ³⁵	48	48	↑ in patients with GAD compared with controls and ↑ with increased severity of GAD. <i>TNF-α</i>
Hoge <i>et al</i> ⁴⁴	–	70	No control group: RCT of psychological intervention in GAD.
Hou <i>et al</i> 2017 ⁴⁷	64	54	↑ in patients with GAD compared with controls which remained ↑ after adjustment for covariates.
Korkeila <i>et al</i> ⁴⁰	116		↑ in non-smoking women with a diagnosis of GAD compared with controls, although control group was not described.
Vogelzangs <i>et al</i> ³⁶	556	454	↔ in patients with GAD compared with controls, and ↔ between <i>TNF-α</i> and GAD compared with other anxiety disorders.
Yang <i>et al</i> ⁴⁵	41	28	↑ sputum <i>TNF-α</i> in patients with GAD aged 50–60 years old compared with controls.
Zahm ⁴¹	728	93	↔ between those with and without a current GAD diagnosis or with and without a lifetime GAD diagnosis, using a combined inflammatory index of CRP, IL-6 and <i>TNF-α</i> measurements. <i>CCL-5/RANTES</i>
Ogłodek <i>et al</i> ⁴⁸	40	120	↑ in men with GAD and comorbid personality disorder compared with controls. <i>MCP-1</i>
Ogłodek <i>et al</i> ⁴⁸	40	120	↑ in GAD and comorbid personality disorder compared with controls. <i>SDF-1</i>
Ogłodek <i>et al</i> ⁴⁸	40	120	↑ in GAD and comorbid personality disorder compared with controls. <i>GM-CSF</i>
Tang <i>et al</i> ³⁵	48	48	↑ in patients with GAD compared with controls and ↑ with increased severity of GAD.

↑, statistically significant increase in inflammatory marker in people with GAD compared with controls ($p < 0.05$); ↓, statistically significant decrease in inflammatory marker in people with GAD compared with controls ($p < 0.05$); ↔, no statistically significant difference in inflammatory marker in people with GAD compared with controls ($p > 0.05$).

BMI, body mass index; CCL-5, chemokine C-C motif ligand 5; CRP, C reactive protein; CVD, cardiovascular disease; GAD, generalised anxiety disorder; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN- γ , interferon- γ ; IL, interleukin; MCP-1, monocyte chemoattractant protein-1; RANTES, regulated on activation, normal T cell expressed and secreted; RCT, randomised controlled trial; SDF-1, stromal derived factor-1; *TNF-α*, tumour necrosis factor- α .

One found a significant positive correlation between CRP level and Generalised Anxiety Disorder Assessment (GAD-7) scores,³⁵ and the other reporting CRP differences in 70 patients with GAD with and without a diagnosis of alexithymia found a significant association between higher CRP and suicidal ideation.⁴²

Although the meta-analysis and the majority of included studies reported raised CRP in GAD, there was wide variation in reporting and adjustment for important potential moderators, including comorbid MDD, use of medications, assay used and time of day of blood collection, all

of which likely contributed to the high degree of heterogeneity between studies. Of the nine studies to analyse CRP, four (44.4%) did not exclude or adjust for medication use by participants.^{33 38 40 41} Comorbid MDD was not adjusted for in the analysis by two studies,^{39 41} one of which was included in the meta-analysis.³⁹ Only three of the nine studies reported time of sample collection^{35 36 42} or whether this was in a fasted state,^{36 41 42} and although all studies used a similar assay method, different assay types were used in every study.

Table 4 Study quality assessment: Newcastle-Ottawa Scale

	Selection		Comparability			Exposure			Total stars
	Adequate case definition	Cases representative	Selection of controls	Definition of controls	Comparability of design and analysis	Ascertainment of exposure	Same method of ascertainment	Non-response rate	
Bankier <i>et al</i> ³⁸	◇	–	◇	◇	◇◇	◇	◇	◇	8
Copeland <i>et al</i> ³⁹	◇	◇	◇	◇	◇◇	◇	◇	–	8
De Berardis <i>et al</i> ⁴²	◇	–	NA	NA	NA	◇	NA	–	2
Hoge <i>et al</i> ⁴⁴	◇	–	NA	NA	NA	◇	NA	–	2
Hou <i>et al</i> ⁴⁷	◇	◇	◇	◇	◇◇	◇	◇	–	8
Khandaker <i>et al</i> ³³	◇	◇	◇	◇	◇◇	◇	◇	◇	9
Korkeila <i>et al</i> ⁴⁰	◇	–	◇	–	◇	–	◇	–	4
Nayek and Ghosh ³⁴	◇	–	◇	–	◇◇	◇	◇	–	6
Oglodek <i>et al</i> ⁴⁸	◇	–	◇	◇	◇◇	–	◇	–	6
Tang <i>et al</i> ³⁵	◇	◇	◇	◇	◇◇	◇	◇	–	8
Tofani <i>et al</i> ⁴⁶	◇	–	–	–	◇	◇	◇	–	4
Vogelzangs <i>et al</i> ³⁶	◇	◇	◇	◇	◇◇	◇	◇	◇	9
Yang <i>et al</i> ⁴⁵	◇	◇	–	◇	◇◇	◇	◇	–	7
Zahm ⁴¹	◇	–	–	–	◇◇	◇	◇	–	5

-, did not meet the criteria; ◇, met criteria for allocation of point on Newcastle-Ottawa scale; ◇◇, two points on Newcastle-Ottawa scale; NA, not applicable.

Table 5 Additional critical appraisal

	Type of publication	Unrepresentative recruitment methods	Unrepresentative demographics	Between-group differences reported	Adjusted for between-group differences
Bankier <i>et al</i> ³⁸	Paper	Yes, recruited from cardiology clinic	Yes, older cohort due to cardiac comorbidity required	NR	NR
Copeland <i>et al</i> ³⁹	Paper	No	Yes, aged 9–21 only	Yes	Yes
De Berardis <i>et al</i> ⁴²	Paper	No	No (aged 18–45)	No control	No control
Hoge <i>et al</i> ⁴⁴	Paper	Yes, recruited by advert as part of parent RCT	No (aged >18)	No control	No control
Hou <i>et al</i> ⁴⁷	Paper	No	No (aged 18–65)	Yes	Yes
Khandaker <i>et al</i> ³³	Paper	No	Yes, aged 16 years old only	Yes	Yes
Korkeila <i>et al</i> ⁴⁰	Abstract	Yes, recruited from existing study in Finland	Yes, non-smoking women only	No	Yes (BMI only)
Nayek and Ghosh ³⁴	Paper	Yes, inpatients only	No (aged 18–65)	Yes	Yes
Ogłodek <i>et al</i> ⁴⁸	Paper	Yes, comorbid personality disorder	No	Yes	No
Tang <i>et al</i> ³⁵	Paper	No	No (aged 18–60)	Yes	Yes
Tofani <i>et al</i> ⁴⁶	Abstract	Recruitment method not stated	NR	NR	NR
Vogelzangs <i>et al</i> ³⁶	Paper	No	No (aged 18–65)	Yes	Yes
Yang <i>et al</i> ⁴⁵	Paper	No	Yes (aged 50–60)	Yes	Yes
Zahm ⁴¹	Dissertation	Yes, cardiology patients only	Yes (aged >50)	Yes	Yes

BMI, body mass index; NR, not reported; RCT, randomised controlled trial.

In summary, of the nine studies to have examined differences between GAD and controls, the majority reported raised CRP in GAD and the meta-analysis found significantly raised CRP in GAD with a small effect size. However, there was a wide variation in study methods, including variable adjustment for mediators of inflammation such as comorbid MDD, medication use and sampling methods. Only one study examined CRP in GAD longitudinally, reporting a bivariate association accounted for by health-seeking behaviours.³⁹

Interleukins

Seven studies examined the association between interleukins and GAD (see table 3). IL-6 is a mediator of T cell and B cell activation and induces acute phase proteins in hepatocytes, among other functions.³² Pharmacological blockade of IL-6 action is used to treat several autoimmune conditions including RA, and raised IL-6 has been associated with a number of psychiatric conditions including depression, schizophrenia and post-traumatic

Figure 2 Random-effects meta-analysis of CRP levels in GAD versus controls. CRP, C reactive protein; GAD, generalised anxiety disorder; Std, standard; IV, inverse variance.

stress disorder (PTSD).^{32 43} We found IL-6 was the most frequently measured interleukin, with five studies (n=2066) examining changes in patients with GAD compared with controls.^{35 36 41 44 45} The largest study investigated differences between 454 participants with a diagnosis of GAD and 556 controls from The Netherlands Study of Depression and Anxiety cohort.³⁶ Although analysis was conducted on anxiety disorders as a whole, the mean difference in IL-6 in people with GAD compared with controls obtained through direct communication with the author showed significantly higher levels in GAD. However, it is unclear whether these differences remain significant after adjustment for group differences and no associations were found between IL-6 and participants who had all types of anxiety disorder.³⁶ Two studies^{35 45} (n=165), one of which used saliva samples,⁴⁵ reported significantly higher IL-6 in medication-naïve participants with a diagnosis of GAD compared with age-matched and sex-matched healthy controls.

No difference was found in a combined inflammatory index consisting of CRP, IL-6 and TNF- α in a study of 93 patients with GAD and comorbid ischaemic heart disease.⁴¹ One case-controlled study³⁵ of 48 Chinese outpatients presenting for the first time with a diagnosis of GAD and 48 age-matched, sex-matched and education-matched controls accounted for all results for IL-1 α , IL-5, IL-8 and IL-12p70. This study found significantly higher levels of IL-1 α , IL-8 and IL-12p70 in patients with GAD, in addition to higher levels of IL-1 α and IL-8 with increased severity of GAD (as measured by the GAD-7 scale), but did not account for chronic physical comorbidities during recruitment or in analysis. Both IL-1 α and IL-8 have proinflammatory functions as chemoattractants for leukocytes and haematopoiesis, and have been targeted for treatments in a number of autoimmune conditions.³² However, there was no association between GAD and IL-5, which is thought to predominantly mediate myeloid cell activation and is a target of treatment in asthma.³² The same study³⁵ also examined IL-2, which has a major role in T cell-mediated autoimmune and inflammatory conditions.³² The results showed significantly higher IL-2 in patients with GAD; however, this conflicted with results from a smaller study (n=24) that found no significant difference between medication-naïve patients with GAD and controls, although few details of the characteristics of participants, sampling or analysis were reported in this abstract.⁴⁶

One study that measured IL-1 using sputum analysis found significantly higher levels in GAD compared with controls in 69 participants recruited from the same Chinese hospital.⁴⁵ Although IL-1 is proinflammatory, there are differences in function, dependent on the class of IL-1 protein measured which was not reported in this study.⁴⁵

IL-4 has several proinflammatory functions, including IgE class switching, expression of major histocompatibility complex (MHC) class II and acts as a survival factor for T and B cells.³² The only study to measure IL-4 found

no differences between 54 patients with GAD recruited from community mental health teams and primary care after controlling for age, sex, BMI, smoking, alcohol consumption and comorbid depression.⁴⁷ This study⁴⁷ also investigated IL-10, which was the only cytokine with an anti-inflammatory function to be measured and is involved in immunosuppression of T cell subsets and B cell immunoglobulin production. This found significantly lower levels of IL-10 (OR 0.35, p=0.003) in patients with GAD. However, this opposed findings from a smaller study (n=24) which reported significantly higher levels of IL-10 in patients with GAD compared with controls, although it was not reported whether this association remained significant after controlling for group differences.⁴⁶

In summary, IL-6 was the most commonly measured interleukin raised in GAD compared with controls in the majority of studies; however, no study examined the longitudinal association with GAD. Other interleukins were examined by relatively few studies that examined small numbers cross-sectionally with mixed findings.

Interferon- γ

IFN- γ has antiviral roles, including promoting cytotoxic activity, MHC class I and II upregulation, natural killer (NK) cell activation, and is a treatment target in inflammatory conditions such as Crohn's disease.³² Three studies investigated IFN- γ levels in GAD (n=330).^{35 40 47} The largest study (n=118) found higher IFN- γ in patients with GAD from the UK that remained significant after adjustment for age, gender, BMI, smoking, alcohol and comorbid depression, but did not adjust for anxiolytic medication use in analysis.⁴⁷ This finding was supported by a study of 96 participants which reported higher IFN- γ levels in GAD and a significant positive correlation between anxiety severity and IFN- γ .³⁵ Conflicting findings were reported by a Finnish study of 116 participants, which found significantly lower IFN- γ in patients with GAD. However, the number of participants with a diagnosis of GAD, differences between groups and adjustment for potential confounders were not reported.⁴⁰ In summary, only a few small cross-sectional studies have examined differences in IFN- γ between GAD and control groups, and their findings were mixed.

Tumour necrosis factor- α

TNF- α has a wide array of roles in host defence, including initiating a strong acute inflammatory response but limiting duration of inflammatory activation, and is the target of blocking monoclonal antibodies in the treatment of a wide array of autoimmune conditions including Crohn's disease and RA.³² Six studies (n=2300) investigated TNF- α in GAD, with mixed findings. Three studies (n=303) found TNF- α significantly raised in patients with GAD compared with controls.^{40 45 47} However, the largest study to measure TNF- α (n=1010) found no difference between participants with GAD and controls, and no correlation between TNF- α and anxiety symptoms.³⁶ This finding was supported by a study of 93 patients

with GAD and comorbid ischaemic heart disease using a combined inflammatory index of CRP, IL-6 and TNF- α which reported no difference compared with controls.⁴¹ In summary, although the majority of the studies to measure differences in TNF- α between GAD and controls reported significantly raised levels, these comprised small cross-sectional studies and the largest study reported no difference.

Other cytokines

One study compared the levels of the proinflammatory cytokines chemokine C-C motif ligand 5 (CCL-5), monocyte chemoattractant protein-1 (MCP-1) and stromal derived factor-1 (SDF-1) in 120 medication-naïve, physically well patients with a diagnosis of GAD and comorbid personality disorder with 40 controls.⁴⁸ Significantly higher levels of MCP-1 and SDF-1 were reported in both men and women, and higher CCL-5 in men but not women with a diagnosis of GAD compared with controls.⁴⁸

DISCUSSION

To our knowledge, this is the first systematic review and meta-analysis focusing on inflammatory cytokines in GAD. Using a range of databases we identified 14 studies, comprising 1188 participants with GAD and which measured 16 cytokines. We found significantly raised levels of CRP, IFN- γ and TNF- α in people with GAD compared with controls, which were findings replicated in two or more studies. A further 10 proinflammatory cytokines were reported to be significantly raised in GAD in at least one study; however, 6 of 14 studies found no difference in at least one cytokine.

Despite substantial efforts to acquire data by contacting the authors, it was only possible to conduct a meta-analysis of CRP. This identified significantly higher levels in GAD compared with controls with a small effect size (SMD=0.38), although there was evidence of significant heterogeneity across studies ($I^2=75\%$). This effect size in CRP is greater than has been reported in other anxiety disorders (PTSD: SMD=-0.14)²⁴ or MDD (SMD=0.14)⁶ and is similar to that reported in schizophrenia (SMD=0.45).⁴⁹ However, the effect size of our meta-analysis was driven by findings in poorer quality studies with small sample sizes. The two higher quality, larger studies reported a smaller effect size and no significant difference between groups, respectively. As a result, further high-quality studies are required to confirm our findings of raised CRP in GAD.

Although we were only able to meta-analyse CRP, meta-analyses of different cytokines in other anxiety disorders have been conducted with larger effect sizes. A meta-analysis of inflammatory markers in PTSD identified 20 studies which reported increased IL-6, IL-1 β , TNF- α and IFN- γ levels, with effect sizes ranging from small (IFN- γ : SMD 0.49) to large 1.42 (IL-1 β : SMD 1.42).²⁴ However, a systematic review and meta-analysis of proinflammatory cytokines in OCD identified 12 studies,

and concluded that there was a significant reduction in IL-1 β with moderate effect size (SMD=-0.60, $p<0.001$), and only IL-6 levels were significantly increased after subgroup analysis in medication-free adults with OCD.⁷ It is unclear whether this profile of inflammatory marker changes would follow a similar pattern in GAD if future studies enabled further meta-analysis.

In light of the high heterogeneity among studies, low participant numbers, and inconsistent reporting and adjustment for known confounding factors such as BMI, smoking, medication use and comorbidities, our findings should be interpreted with caution. It was not possible to analyse the cause of the degree of heterogeneity due to the paucity of studies. Other known mediators of inflammation²⁴ such as physical activity, raised blood pressure and genetics were not accounted for. Furthermore, reporting of GAD severity and duration of symptoms was generally poor, preventing detailed analysis of whether inflammatory markers predicted outcomes and quality of life. We also found limitations in inclusion of specific demographics of participants with GAD. For example, despite GAD in older adults being prevalent and often treatment-resistant,⁵⁰⁻⁵² only two studies included participants over the age of 65, both of which only included patients with comorbid ischaemic heart disease.

We are beginning to understand the interplay between cytokines, the immune system and mental health.^{1 53} At a molecular level we are aware that proinflammatory cytokines, including IFN, IL-1 β and TNF, can reduce the availability of monoamines by inducing expression of presynaptic reuptake pumps and inhibiting enzymes involved in monoamine synthesis,⁵⁴ linking the monoamine theory of anxiety with inflammatory mechanisms. There is also a growing understanding of the relationship between systemic inflammation and the central nervous system (CNS).^{1 55} Microglial activation has been shown to be mediated by peripheral cytokines, and increased activation has been found in postmortem studies of patients with MDD and schizophrenia.¹ No study we identified correlated inflammatory marker changes with in vivo microglial activation imaging in GAD, and to our knowledge no research on postmortem microglial changes in GAD has been conducted. Increased neuronal activity has also been shown to induce inflammatory and vascular changes in the brain, suggesting that psychological stress can not only be induced by inflammation but perpetuate chronic low-grade inflammation seen in other vascular and neurodegenerative disorders.⁵⁵ Understanding interactions between the CNS and immune system and identifying biomarkers of GAD offer potential for novel therapeutic approaches. The revolution of development of monoclonal-antibody therapies for inflammatory disorders⁵⁶ raises the possibility of repurposing these medications for trials in treatment-resistant GAD if specific and consistent profiles of inflammatory biomarkers are identified.

However, it remains unclear as to whether inflammation plays a causal role in GAD.^{43 54} For example, although

IL-6 is a successful target for treatment in a number of autoimmune conditions and raised IL-6 is implicated in several psychiatric disorders, it also acts to reduce other proinflammatory cytokines such as TNF via negative feedback and is induced by physical exercise, hyperthermia, fasting, sleep deprivation and sunlight exposure without activation of other proinflammatory cytokines.⁴³ This raises the question as to whether inflammation in GAD is a consequence rather than a cause of symptoms. This will only be answered by large prospective longitudinal studies, better characterising the relationship between inflammation and GAD. However, remarkably our review identified only one longitudinal study of inflammation in patients with GAD that examined a cohort of adolescents until the age of 21 and only investigated CRP.

Recent studies using Mendelian randomisation in depression have suggested that cytokines such as IL-6 are causal risk factors for depression,⁵⁷ and trials of immunotherapy in psychosis are already under way.⁵⁸ Our study suggests that GAD is an important candidate for future similar studies exploring causality of inflammation and potentially novel drug trials.

CONCLUSION

There is some preliminary evidence to suggest a raised inflammatory response in GAD, although it is unclear whether inflammatory cytokines play a role in the aetiology. GAD remains a poorly studied area of psychiatric neuroinflammatory research compared with other mental illnesses such as MDD and schizophrenia. While we are a long way from using inflammatory cytokines as a biomarker or treatment target in GAD, current findings reflect inflammatory changes seen in other mental illnesses and highlight the importance of ongoing investigation of the role inflammation plays in the development and course of GAD. Further, methodologically consistent, prospective, longitudinal studies examining the mechanisms and relationship between inflammation and GAD, while accounting for known mediators of cytokine production, are required.

Contributors RH, RLG and HC were involved in the initial design of the research. EA and HC performed the data extraction of the included studies and quality analysis. HC wrote the initial draft of the manuscript and did the statistical analysis, with supervision from RLG and RH. RH, RLG and HC participated in the critical revision of the article, and all authors approved the final article.

Funding HC and EA are NIHR Academic Clinical Fellows (ACF). This research was supported by the NIHR Biomedical Research Centre at University College London/ University College Hospital London.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement All data extracted for this systematic review and meta-analysis are available via direct contact with HC.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given,

and indication of whether changes were made. See: <https://creativecommons.org/licenses/by/4.0/>.

REFERENCES

1. Réus GZ, Fries GR, Stertz L, *et al.* The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders. *Neuroscience* 2015;300:141–54.
2. Brown AS, Vinogradov S, Kremen WS, *et al.* Prenatal exposure to maternal infection and executive dysfunction in adult schizophrenia. *Am J Psychiatry* 2009;166:683–90.
3. Benros ME, Waltoft BL, Nordentoft M, *et al.* Autoimmune diseases and severe infections as risk factors for mood disorders: a nationwide study. *JAMA Psychiatry* 2013;70:812.
4. O'dushlaine C, Rossin L, Lee PH, *et al.* Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. *Nat Neurosci* 2015;18:199–209.
5. Khandaker GM, Cousins L, Deakin J, *et al.* Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. *Lancet Psychiatry* 2015;2:258–70.
6. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. *Psychosom Med* 2009;71:171–86.
7. Gray SM, Bloch MH. Systematic review of proinflammatory cytokines in obsessive-compulsive disorder. *Curr Psychiatry Rep* 2012;14:220–8.
8. Munkholm K, Vinberg M, Vedel Kessing L. Cytokines in bipolar disorder: a systematic review and meta-analysis. *J Affect Disord* 2013;144:16–27.
9. Meyer U, Feldon J. Neural basis of psychosis-related behaviour in the infection model of schizophrenia. *Behav Brain Res* 2009;204:322–34.
10. Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. *Mol Psychiatry* 2016;21:1696–709.
11. Rao JS, Harry GJ, Rapoport SI, *et al.* Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. *Mol Psychiatry* 2010;15:384–92.
12. Khairova RA, Machado-Vieira R, Du J, *et al.* A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. *Int J Neuropsychopharmacol* 2009;12:561.
13. Kubera M, Obuchowicz E, Goehler L, *et al.* In animal models, psychosocial stress-induced (neuro)inflammation, apoptosis and reduced neurogenesis are associated to the onset of depression. *Prog Neuropsychopharmacol Biol Psychiatry* 2011;35:744–59.
14. Furtado M, Katzman MA. Neuroinflammatory pathways in anxiety, posttraumatic stress, and obsessive compulsive disorders. *Psychiatry Res* 2015;229:37–48.
15. Andlin-Sobocki P, Wittchen HU. Cost of anxiety disorders in Europe. *Eur J Neurol* 2005;12 Suppl 1:39–44.
16. Baxter AJ, Scott KM, Vos T, *et al.* Global prevalence of anxiety disorders: a systematic review and meta-regression. *Psychol Med* 2013;43:897–910.
17. Bystritsky A. Treatment-resistant anxiety disorders. *Mol Psychiatry* 2006;11:805–14.
18. Bruce SE, Yonkers KA, Otto MW, *et al.* Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. *Am J Psychiatry* 2005;162:1179–87.
19. Baldwin D, Woods R, Lawson R, *et al.* Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. *BMJ* 2011;342:d1199.
20. Cuijpers P, Sijbrandij M, Koole S, *et al.* Psychological treatment of generalized anxiety disorder: a meta-analysis. *Clin Psychol Rev* 2014;34:130–40.
21. Härter MC, Conway KP, Merikangas KR. Associations between anxiety disorders and physical illness. *Eur Arch Psychiatry Clin Neurosci* 2003;253:313–20.
22. Roy-Byrne PP, Davidson KW, Kessler RC, *et al.* Anxiety disorders and comorbid medical illness. *Gen Hosp Psychiatry* 2008;30:208–25.
23. Uguz F, Akman C, Kucuksarac S, *et al.* Anti-tumor necrosis factor- α therapy is associated with less frequent mood and anxiety disorders in patients with rheumatoid arthritis. *Psychiatry Clin Neurosci* 2009;63:50–5.
24. Passos IC, Vasconcelos-Moreno MP, Costa LG, *et al.* Inflammatory markers in post-traumatic stress disorder: a systematic review, meta-analysis, and meta-regression. *Lancet Psychiatry* 2015;2:1002–12.

25. Michopoulos V, Powers A, Gillespie CF, *et al.* Inflammation in Fear- and Anxiety-Based Disorders: PTSD, GAD, and Beyond. *Neuropsychopharmacology* 2017;42:254–70.
26. Liberati A, Altman DG, Tetzlaff J, *et al.* The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *J Clin Epidemiol* 2009;62:e1–34.
27. Spitzer R, Williams J, Gibbon M, *et al.* Structured Clinical Interview for DSM-IV. *Encyclopedia of Behavioral Medicine* 1994.
28. Wells G, Shea B, O'Connell D, *et al.* The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Meta-Analyses. 2013.
29. Higgins JP, Thompson SG, Deeks JJ, *et al.* Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557–60.
30. Kitahara CM, Trabert B, Katki HA, *et al.* Body mass index, physical activity, and serum markers of inflammation, immunity, and insulin resistance. *Cancer Epidemiol Biomarkers Prev* 2014;23:2840–9.
31. Petrovsky N, McNair P, Harrison LC. Diurnal rhythms of pro-inflammatory cytokines: regulation by plasma cortisol and therapeutic implications. *Cytokine* 1998;10:307–12.
32. Akdis M, Aab A, Altunbulakli C, *et al.* Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β , and TNF- α : Receptors, functions, and roles in diseases. *J Allergy Clin Immunol* 2016.
33. Khandaker GM, Zammit S, Lewis G, *et al.* Association between serum C-reactive protein and DSM-IV generalized anxiety disorder in adolescence: Findings from the ALSPAC cohort. *Neurobiol Stress* 2016;4:55–61.
34. Nayek S, Ghosh S. A comparative study of serum C-Reactive protein in patients with generalised anxiety disorder and depression. *Indian J Psychiatry* 2017;59:S217.
35. Tang Z, Ye G, Chen X, *et al.* Peripheral proinflammatory cytokines in Chinese patients with generalised anxiety disorder. *J Affect Disord* 2018;225:593–8.
36. Vogelzangs N, Beekman AT, de Jonge P, *et al.* Anxiety disorders and inflammation in a large adult cohort. *Transl Psychiatry* 2013;3:e249.
37. Sterne JA, Sutton AJ, Ioannidis JP, *et al.* Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. *BMJ* 2011;343:d4002.
38. Bankier B, Barajas J, Martinez-Rumayor A, *et al.* Association between C-reactive protein and generalized anxiety disorder in stable coronary heart disease patients. *Eur Heart J* 2008;29:2212–7.
39. Copeland WE, Shanahan L, Worthman C, *et al.* Generalized anxiety and C-reactive protein levels: a prospective, longitudinal analysis. *Psychol Med* 2012;42:2641–50.
40. Korkela J, Runsten S, Ollikainen S, *et al.* Generalized anxiety disorder and immunity markers in a stratified population sample. *Eur Psychiatry* 2010;25.
41. Zahm JL. Generalized anxiety disorder and inflammatory biomarkers in coronary heart disease: Sex-specific effects. *Diss Abstr Int Sect B Sci Eng* 2018;78.
42. De Berardis D, Serroni N, Campanella D, *et al.* Alexithymia, suicide ideation, c-reactive protein, and serum lipid levels among outpatients with generalized anxiety disorder. *Arch Suicide Res* 2017;21:100–12.
43. Raison CL, Knight JM, Pariente C. Interleukin (IL)-6: A good kid hanging out with bad friends (and why sauna is good for health). *Brain Behav Immun* 2018;73:1–2.
44. Hoge EA, Bui E, Palitz SA, *et al.* The effect of mindfulness meditation training on biological acute stress responses in generalized anxiety disorder. *Psychiatry Res* 2018;262:328–32.
45. Yang CJ, Liu D, Xu ZS, *et al.* The pro-inflammatory cytokines, salivary cortisol and alpha-amylase are associated with generalized anxiety disorder (GAD) in patients with asthma. *Neurosci Lett* 2017;656:15–21.
46. Tofani T, Di Cesare Mannelli L, Zanardelli M, *et al.* P.1.f.003 An immunologic profile study in drug-naïve generalized anxiety non depressed patients: a pilot study. *European Neuropsychopharmacology* 2015;25:S226.
47. Hou R, Garner M, Holmes C, *et al.* Peripheral inflammatory cytokines and immune balance in Generalised Anxiety Disorder: Case-controlled study. *Brain Behav Immun* 2017;62:212–8.
48. Ogotdek EA, Szota AM, Just MJ, *et al.* The MCP-1, CCL-5 and SDF-1 chemokines as pro-inflammatory markers in generalized anxiety disorder and personality disorders. *Pharmacol Rep* 2015;67:85–9.
49. Miller BJ, Culppepper N, Rapaport MH. C-reactive protein levels in schizophrenia: a review and meta-analysis. *Clin Schizophr Relat Psychoses* 2014;7:223–30.
50. Byers AL, Yaffe K, Covinsky KE, *et al.* High occurrence of mood and anxiety disorders among older adults: The National Comorbidity Survey Replication. *Arch Gen Psychiatry* 2010;67:489–96.
51. Wolitzky-Taylor KB, Castriotta N, Lenze EJ, *et al.* Anxiety disorders in older adults: a comprehensive review. *Depress Anxiety* 2010;27:190–211.
52. Wetherell JL, Afari N, Ayers CR, *et al.* Acceptance and commitment therapy for generalized anxiety disorder in older adults: a preliminary report. *Behav Ther* 2011;42:127–34.
53. Felger JC, Lotrich FE. Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. *Neuroscience* 2013;246:199–229.
54. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. *Nat Rev Immunol* 2016;16:22–34.
55. Xanthos DN, Sandkühler J. Neurogenic neuroinflammation: inflammatory CNS reactions in response to neuronal activity. *Nat Rev Neurosci* 2014;15:43–53.
56. Reichert JM, Rosensweig CJ, Faden LB, *et al.* Monoclonal antibody successes in the clinic. *Nat Biotechnol* 2005;23:1073–8.
57. Khandaker GM, Zuber V, Rees JMB, *et al.* Shared mechanisms between coronary heart disease and depression: findings from a large UK general population-based cohort. *Mol Psychiatry* 2019.
58. Miller BJ, Buckley PF. The Case for Adjunctive Monoclonal Antibody Immunotherapy in Schizophrenia. *Psychiatr Clin North Am* 2016;39:187–98.